Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Ventricular fibrillation/tachycardia].

Yoshifusa Aizawa1

  • 1Division of Cardiology, Niigata University, Graduate School of Medicine.

Nihon Rinsho. Japanese Journal of Clinical Medicine
|July 26, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Is ischemic stimulus involved for J wave augmentation during coronary angiography and intracoronary administration of normal saline?

Pacing and clinical electrophysiology : PACE·2024
Same author

Atrial electrical remodeling and function after transcatheter aortic valve replacement in patients with aortic stenosis.

Heart and vessels·2023
Same author

J wave dynamicity during coronary angiography and intracoronary acetylcholine administration.

Pacing and clinical electrophysiology : PACE·2023
Same author

Sodium-Glucose Cotransporter-2 Inhibitors and Lower-Extremity Amputation.

The American journal of cardiology·2023
Same author

J Waves Augmented by Isoproterenol and Pacing.

Internal medicine (Tokyo, Japan)·2023
Same author

Tissue repair after pulsed field ablation.

Heart rhythm·2022
Same journal

[Development of novel therapeutics for multiple myeloma and improvement of drug lag].

Nihon rinsho. Japanese journal of clinical medicine·2019
Same journal

[Clinical pharmacy services to patients of immunomodulatory drugs].

Nihon rinsho. Japanese journal of clinical medicine·2019
Same journal

[Therapeutic drug monitoring of the new anti-myeloma drugs in the treatment of multiple myeloma].

Nihon rinsho. Japanese journal of clinical medicine·2019
Same journal

[Prognostic value of minimal residual disease assessment using next-generation sequencing in multiple myeloma].

Nihon rinsho. Japanese journal of clinical medicine·2019
Same journal

[The evaluation of minimal residual disease in multiple myeloma by an allele-specific oligonucleotide real-time PCR].

Nihon rinsho. Japanese journal of clinical medicine·2019
Same journal

[Evaluation of minimal residual disease in myeloma by multiparametric flow cytometry].

Nihon rinsho. Japanese journal of clinical medicine·2019
See all related articles

Pulseless tachycardia, including ventricular fibrillation and rapid ventricular tachycardia, requires immediate treatment. While antiarrhythmic drugs and catheter ablation have limitations, implantable cardioverter-defibrillators (ICDs) offer the most reliable therapy for these life-threatening arrhythmias.

Area of Science:

  • Cardiac Electrophysiology
  • Arrhythmology
  • Clinical Cardiology

Context:

  • Ventricular fibrillation and rapid ventricular tachycardia (pulseless tachycardia) are life-threatening arrhythmias requiring urgent intervention.
  • Sustained monomorphic ventricular tachycardia carries a significant risk of poor prognosis.
  • Electrophysiologic studies are crucial for risk stratification following diagnosis.

Purpose:

  • To review the current therapeutic strategies for fatal ventricular arrhythmias.
  • To evaluate the efficacy and limitations of antiarrhythmic drugs, catheter ablation, and implantable cardioverter-defibrillators (ICDs).

Summary:

  • Antiarrhythmic drug therapy demonstrates limited efficacy for these severe arrhythmias.
  • Catheter ablation offers a potential cure but has a success rate of 50-70% in selected patients.

Related Experiment Videos

  • Implantable cardioverter-defibrillators (ICDs) are currently the most reliable therapeutic option for symptomatic patients.

    • Impact:

    • Highlights the limitations of current treatments for life-threatening ventricular arrhythmias.
    • Emphasizes the role of ICDs as the primary therapy.
    • Suggests considering antiarrhythmic drugs or catheter ablation as adjunctive treatments.